SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paracelsian Inc (PRLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Richard Mazzarella who wrote (347)8/30/1996 11:53:00 PM
From: WWS   of 4342
 
Richard, I thought that PRLN was going to first release product as nutritional supplement. This is what they alluded to in the conference call. Presumably, this would enable them to raise the hundreds of millions that they'll need to develop a full fledged new drug application. But in your talk Koch seemed to indicate that "royalty arrangements" with the conglomerates is the way to go. Seems to me that they'd better decide quickly on a single marketing strategy. If Pn355 works (the big IF) either alone or in combination its projected low cost will force the government to "fast track" its development. As you pointed out in previous post, the third world (source of 90% of all HIV/AIDS) cannot afford the current regime of AZT+protease inhibitor+reverse transcriptase inhibitor at upwards of $15,000/year. BTW, last word I got on Pn355 was that it began 90-day Phase 1 trial in February with just 10 patients at Bastyn U. in Seattle. Any update on the status of this group or othes like it? Bill in St. Louis
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News